Impact of Body Composition Changes on Treatment-Related Toxicities and Clinical Outcomes in HER2-Positive Metastatic Breast Cancer Patients Receiving Trastuzumab Deruxtecan
Changes in body composition, particularly reductions in SMA, were associated with increased treatment discontinuation and mortality in HER2-positive metastatic breast cancer receiving T-DXd. Increase in SAT was associated with higher rates of severe toxicities, highlighting its potential role in predicting treatment-related complications, and the clinical relevance of nutritional changes on outcomes in this setting.
Authors
- Mario Ardovino
- Alessio Molfino (ORCID: https://orcid.org/0000-0002-6432-0236)
- Andrea Botticelli (ORCID: https://orcid.org/0000-0002-6425-9893)
- Simona Pisegna (ORCID: https://orcid.org/0000-0002-6910-9528)
- Simone Scagnoli (ORCID: https://orcid.org/0000-0003-4943-5622)
- Veronica Rizzo (ORCID: https://orcid.org/0000-0003-1781-3174)
- Giovanni Imbimbo (ORCID: https://orcid.org/0000-0001-8149-9154)
- Carmen Gallicchio
- Claudia Alabiso
Institutions
- Sapienza University of Rome (IT)
Publication Details
- Journal
- Cancers
- Published
- 2025-09-19
- DOI
- https://doi.org/10.3390/cancers17183063
- Citations
- 1
- Primary Topic
- Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.05